达雷妥尤单抗为基础的方案治疗肾脏意义单克隆丙种球蛋白病患者的疗效与安全性
该研究回顾性总结了25例肾脏意义单克隆丙种球蛋白病(MGRS)患者接受达雷妥尤单抗为基础治疗的经验,其中12例既往未治疗,中位随访14个月,总体血液学缓解率74%,6个月时55%非透析患者蛋白尿下降>30%且不伴eGFR下降,毒性轻微可预测,作者认为达雷妥尤单抗为基础治疗是MGRS的新选择。
要点
- 可评估患者总体血液学缓解率74%,完全缓解5例(22%),非常好的部分缓解5例(22%),部分缓解7例(30%)。
- 既往未治疗患者缓解率83% vs 既往治疗患者69%,达雷妥尤单抗联合方案91% vs 单药64%。
- 6个月时12/22(55%)非透析患者蛋白尿下降>30%(至少0.5 g/24h)且eGFR无下降。
核心结论
- 作者认为,以达雷妥尤单抗为基础的治疗是MGRS患者的一种新选择。
研究设计与样本
- 该研究总结了25例MGRS患者使用以达雷妥尤单抗为基础治疗的经验,其中12例既往未治疗,队列中位随访14个月。
主要发现
- 可评估患者的最佳总体血液学缓解为完全缓解5例(22%)、非常好的部分缓解5例(22%)、部分缓解7例(30%),总体缓解率74%。
- 5例完全缓解患者中2例、以及2例初始可检测克隆但免疫球蛋白不可测的患者,治疗后采用下一代流式细胞术(NGF)检测微小残留病(MRD)为不可测。
- 既往未治疗患者的血液学缓解率为83%,既往治疗患者为69%;达雷妥尤单抗联合方案为91%,单药为64%;完全缓解/非常好的部分缓解率联合方案为82%,单药为29%。
- 6个月时,22例非透析患者中12例(55%)实现蛋白尿下降>30%(至少0.5 g/24h),且不伴估算肾小球滤过率(eGFR)下降。
- 毒性轻微且可预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of the plasma cell clone in monoclonal gammopathy of renal significance (MGRS) is necessary in order to reduce toxic immunoglobulin load to the kidneys and salvage renal function. There are limited data on the use of daratumumab in patients with MGRS. We summarize our experience with the use of daratumumab-based therapy in 25 MGRS patients, 12 of whom were previously untreated. The median follow-up of the cohort is 14 months. The best overall haematologic response in evaluable patients was complete response (CR) in five (22%), very good partial response (VGPR) in five (22%) and partial response (PR) in seven (30%) patients for an overall response rate of 74%. Two of five patients in CR and two patients with initially detectable clones, but non-measurable immunoglobulins, had undetectable minimal residual disease (MRD) with next-generation flow cytometry (NGF) after therapy. Haematologic response rate for previously untreated patients was 83% vs. 69% for previously treated and for daratumumab combinations it was 91% vs. 64%, and with CR/VGPR 82% vs. 29%, compared to daratumumab monotherapy. At six months, 12/22 (55%) patients not on dialysis achieved a reduction of proteinuria >30%, of at least 0·5 g/24 h, without an estimated glomerular filtration rate (eGFR) reduction. The toxicity was mild and predictable. In conclusion, daratumumab-based therapy is a new option for patients with MGRS.
引用
- Kastritis E, Theodorakakou F, Roussou M, et al. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. Br J Haematol. 2020. PMID: 32829529. doi:10.1111/bjh.17052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。